Read more

December 11, 2019
1 min read
Save

ImprimisRx outsourcing facility receives California license

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

An FDA-registered 503B outsourcing facility for ImprimisRx has received a non-resident operating license from the state of California, the company announced in a press release.

Perspective from Michael Rauser, MD

ImprimisRx, a wholly owned subsidiary of Harrow Health, will now be able to provide its ophthalmic products to ophthalmologists, optometrists, surgery centers and hospitals in the state.

“The expected impact to ImprimisRx from this new license cannot be understated. While our business as a whole continues to grow nationally, we now expect California demand to significantly pick up and for California-specific sales to increase as a percentage of our overall revenue,” John Saharek, ImprimisRx president, said in the release. “This California 503B license is coming at a great time as recent investments we’ve made in automated equipment, personnel and training are expected to increase our production capacity, easily allowing us to absorb the anticipated new demand.”